Partnership / Collaboration · GCC · Announced 15 Jun 2026

Glaxo Saudi Arabia → AJA Pharma

AJA Pharma, a Saudi Chemical Holding subsidiary, signed a three-year non-exclusive agreement to provide medical marketing services for GSK's pharmaceutical products in Saudi Arabia, paid as a share of GSK's Saudi sales.

Parties: Glaxo Saudi Arabia (GSK) (Saudi Arabia) → AJA Pharma (Saudi Arabia)

Value
Undisclosed
Territory
Saudi Arabia
Therapeutic area
Multi-therapy
Asset
GSK pharmaceutical portfolio (products not named)
Announced
15 Jun 2026

Our analysis

Why this matters

AJA Pharmaceutical Industries (AJA Pharma), a subsidiary of Tadawul-listed Saudi Chemical Holding, signed a non-exclusive agreement with Glaxo Saudi Arabia Limited (GSK) on 15 June 2026 to provide medical marketing services for a wide range of GSK pharmaceutical products in Saudi Arabia, using AJA's medical field teams. The term is three years with an option to renew. Consideration is a percentage of GSK's Saudi sales, plus performance indicators and operational targets, and Saudi Chemical expects the annual value to be below 5% of group revenues. Financial impact was expected from Q3 2026.

A global originator contracting out field promotion to a local manufacturer is a sign of where multinational cost structures are heading in the Gulf. For CFOs, it turns a fixed sales-force cost into a variable, sales-linked fee.

The full analysis is free to read with a work email on this page.

Source: Saudiweek (citing Tadawul filing)

More deals involving Glaxo Saudi Arabia or AJA Pharma

Latest deals

All GCC deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →